Niagen Bioscience (NAGE) Research & Development (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Research & Development of $1.5 million for Q1 2026, up 17.73% year-over-year from $1.3 million in Q1 2025, and down 13.39% quarter-over-quarter from $1.7 million in Q4 2025.
Niagen Bioscience (NAGE) Research & Development (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Research & Development for 17 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 17.73% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.6 million (down 64.26% YoY), while the FY2025 annual figure was $6.3 million, down 78.52% from the prior year.
- Research & Development retreated to $1.5 million in Q1 2026 per NAGE's latest filing, from $1.7 million in the prior quarter.
- Across five years, Research & Development topped out at $24.8 million in Q4 2022 and bottomed at $1.2 million in Q1 2023.
- Historically, Research & Development has averaged $5.5 million across 5 years, with a median of $1.7 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development surged 946.63% — and 2023, when it sank 85.52%.
- Niagen Bioscience's Research & Development stood at $24.8 million in 2022, then declined by 8.59% to $22.6 million in 2023, then slumped by 61.5% to $8.7 million in 2024, then slumped by 80.38% to $1.7 million in 2025, then decreased by 13.39% to $1.5 million in 2026.
- Business Quant data shows NAGE's Research & Development at $1.5 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 10.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.13 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 8.72 Mn |
| Sep 30, 2024 | 7.04 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 22.64 Mn |
| Sep 30, 2023 | 1.24 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 24.77 Mn |
| Sep 30, 2022 | 5.87 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Mar 31, 2022 | 8.24 Mn |
| Dec 31, 2021 | 25.57 Mn |
| Sep 30, 2021 | 996,000.00 |